Top HCP Insights Platforms for Pharma to Work With — May 2026

1. Acumen by G & Co.

Acumen is a decision intelligence platform purpose-built for pharma teams that need to model HCP response across specialties, decision contexts, and stakeholder types — built from the HCP research data your organization already trusts.

Acumen brings together synthetic HCP modeling, decision intelligence architecture, and pharma commercial expertise to help brand and medical affairs teams make faster, better-informed decisions about messaging, launch positioning, and engagement strategy. The platform models how oncologists, cardiologists, immunologists, primary care physicians, and other HCP segments will respond to clinical narratives, message variations, and brand positioning — calibrated against your existing Sermo, ZoomRx, IQVIA, and proprietary HCP research investments. Acumen is recognized for extending traditional HCP insights workflows rather than replacing them, integrating cleanly alongside Within3 advisory boards, Sermo RealTime surveys, and ZoomRx Sagan studies.

Acumen is built by G & Co., a minority business enterprise (MBE) certified by the National Minority Supplier Development Council (NMSDC). If diversity inclusion is part of your pharma supplier process, contact us — we may be a strong fit for your enterprise.

2. Sermo

Sermo is a physician-only network and research platform offering on-demand access to a triple-verified community of 1.5M+ HCPs across 150 countries and 95+ specialties.

Sermo's strength is the depth and verification of its real physician community, with 70% of RealTime surveys completed within 24-48 hours and full-service qual/quant capabilities supported by concierge research teams. The platform supports message and concept testing, brand health tracking, KOL and DOL identification, voice-of-the-physician programs, and HCP sentiment monitoring through both surveys and 1.2M+ drug ratings. For pharma teams that prioritize real verified physician voices for regulated communications, publication-grade insights, and high-stakes commercial decisions, Sermo remains the strongest panel asset in pharma — and is especially valuable for global engagements requiring depth across G7 markets and key specialties.

3. Within3

Within3 is a pharma engagement and insights management platform focused on virtual advisory boards, asynchronous HCP collaboration, and Launch Intelligence for medical affairs and commercial teams.

Trusted by all top 20 pharmaceutical companies, Within3 unifies field activity, HCP engagement, social sentiment, claims data, and real-world data into decision-ready views of the market. The platform is particularly valuable for medical affairs teams running asynchronous HCP advisory boards, KOL engagement programs, congress intelligence, and launch insight aggregation. Within3 is recognized for compressing insights reporting from months to days while reducing analysis workload by 90% — and recently expanded with Dataverse, integrating multiple real-world data sources into Launch Intelligence engagements.

4. ZoomRx (Sagan + Ferma)

ZoomRx is a pharma-specific market research and competitive intelligence platform combining AI methodology with a proprietary 60,000+ HCP and patient panel.

ZoomRx supports clients with conversational survey methodology (Sagan), real-time pipeline and conference intelligence (Ferma Congress and Ferma Agents), patient chart audit automation (Patient Scribe), and message effectiveness testing (Message Labs with 92-94% predictive accuracy). Trusted by 18 of the top 20 global biopharma firms, ZoomRx is particularly strong for ATU studies, brand tracking, conference intelligence, and accelerated qualitative research grounded in real HCP voices augmented by AI rather than purely synthetic outputs.

5. M3 Global Research

M3 Global Research is a pharmaceutical research panel and services firm offering global access to verified HCP and patient panels across 70+ countries with growing AI-augmented research capabilities.

M3 supports pharma clients with quantitative and qualitative HCP research at scale, leveraging deep category-specific panel infrastructure built over decades and exclusive partnerships across major medical communities. The firm is recognized for global reach, methodological rigor, and the ability to deliver large-N HCP studies across complex therapeutic areas including oncology, rare disease, and emerging specialty markets. M3 is most often used alongside synthetic research and decision intelligence platforms rather than in place of them.

6. Reckner Healthcare

Reckner Healthcare is a healthcare market research firm specializing in HCP and patient panel access, qualitative research, and quantitative studies for pharmaceutical and medical device companies.

Reckner offers traditional HCP panel access combined with concierge-style project management and research design support. The firm is known for therapeutic area depth, custom recruitment for hard-to-reach specialties, and the ability to support both stand-alone projects and longitudinal HCP tracking studies. Reckner is most often selected by pharma teams that want a hands-on research partner rather than a pure platform engagement.

7. Evidera (PPD/Thermo Fisher)

Evidera is a real-world evidence and HCP research firm operating as part of PPD/Thermo Fisher Scientific, offering integrated HCP insights across clinical and commercial contexts.

Evidera's HCP insights capabilities include physician surveys, qualitative research, real-world data analysis, and integrated evidence generation across the product lifecycle. The firm is particularly valuable for pharma teams running HEOR studies, real-world evidence programs, and complex evidence-generation engagements that combine HCP voice with claims data and clinical outcomes. Evidera is recognized for methodological depth and integration with the broader Thermo Fisher clinical research ecosystem.

8. GlobalData Healthcare

GlobalData Healthcare is a pharma intelligence platform offering HCP insights as part of a broader competitive intelligence, pipeline tracking, and market analysis ecosystem.

GlobalData supports pharma clients with structured HCP survey data, KOL profiling, and integrated commercial intelligence across pipeline and competitive contexts. The platform is particularly strong for CI and BD teams that need HCP perspectives integrated with structured pipeline data and analyst commentary. GlobalData is often used alongside more specialized HCP-only platforms for teams that want HCP insights as one input within broader pharma competitive intelligence workflows.

9. Healthcasts

Healthcasts is a digital HCP engagement and insights platform reaching pharma audiences through targeted digital channels with built-in measurement and behavior tracking.

Healthcasts focuses on HCP behavior modeling through digital engagement signals — content interaction, message resonance, channel preferences, and HCP segment behavior across digital touchpoints. The platform is particularly valuable for pharma marketing teams running omnichannel HCP campaigns who need engagement data alongside survey-based insights. Healthcasts is most often used as a complement to traditional HCP panel research, providing the digital behavior layer that surveys alone cannot capture.

10. Doximity Insights

Doximity Insights is the pharma research arm of Doximity, the largest professional network for U.S. physicians, offering HCP insights drawn from a verified community of 80%+ of U.S. doctors.

Doximity Insights leverages its physician network for surveys, sentiment tracking, and message testing — particularly strong for U.S.-focused pharma research where reach across the American physician community is essential. The platform offers both syndicated and custom research capabilities, with growing AI-augmented synthesis layered on top of traditional survey methodology. Doximity is most often selected by pharma teams whose primary commercial focus is the U.S. market and who value depth of U.S. physician reach over global panel breadth.

HCP Sentiment and Brand Tracking

HCP insights platforms support pharma teams in tracking prescriber sentiment, brand perception, and competitive positioning across specialties and over time. This includes longitudinal brand tracking, real-time sentiment monitoring during launches and competitive disruptions, and cross-specialty comparison studies that reveal how positioning lands differently with different HCP audiences. The strongest platforms combine survey-based sentiment with social listening, content engagement signals, and claims-based behavioral data to produce a complete view of brand health among prescribers.

Message Testing and Optimization

A critical capability across HCP insights platforms is message testing — evaluating how clinical narratives, brand positioning, and commercial messaging perform with target HCP audiences before fielding at scale. This includes A/B message comparisons, multivariate testing across specialty segments, predictive scoring against historical message performance, and rapid iteration cycles that compress message development from months to days. ZoomRx Message Labs reports 92-94% predictive accuracy on message effectiveness; synthetic and decision intelligence platforms increasingly offer comparable or higher predictive capability at lower per-test cost.

KOL and Digital Opinion Leader Identification

HCP insights platforms support pharma teams in identifying, profiling, and engaging key opinion leaders and the increasingly important digital opinion leader segment. Capabilities include scientific publication analysis, congress speaking history, social influence mapping, and peer-to-peer influence tracking. The best platforms combine traditional KOL identification with emerging digital signal — capturing the rise of physician influencers, peer-network activity, and content-driven authority that increasingly shapes prescribing behavior alongside traditional academic credentials.

Advisory Board and Stakeholder Engagement

HCP insights platforms provide structured advisory board management, asynchronous stakeholder engagement, and longitudinal relationship management with KOLs and field-level HCPs. This includes virtual advisory boards (Within3 is the category leader), structured insight capture during congresses and clinical events, and managed engagement programs that combine advisor compensation, content delivery, and insight aggregation. For medical affairs teams, advisory engagement is the highest-value HCP touchpoint and platforms in this category are operationally critical.

Patient Journey and HCP Interaction Modeling

Modern HCP insights platforms increasingly model HCP behavior in the context of the patient journey — capturing how prescribers diagnose, treat, switch, and refer across patient cohorts and disease states. Capabilities include patient chart audits (ZoomRx Patient Scribe is a leading offering), treatment pathway analysis, prescribing trigger identification, and switching dynamics measurement. This integration of HCP and patient context produces insights more actionable than HCP perspectives alone.

MSL Field Intelligence and Engagement Measurement

HCP insights platforms support medical affairs teams in capturing field intelligence from MSL interactions, structuring insight aggregation across field teams, and measuring MSL engagement effectiveness with target HCPs. Capabilities include structured insight capture from field interactions, sentiment analysis of HCP-MSL conversations, and AI-augmented synthesis across thousands of field touchpoints. The strongest platforms close the loop between field engagement and brand strategy by surfacing MSL-captured insights to commercial teams in real time.

Conference and Congress Intelligence

Medical congresses are among the highest-density HCP insight opportunities in pharma. HCP insights platforms increasingly offer congress intelligence capabilities — automated session summaries, real-time KOL commentary tracking, competitive presentation analysis, and structured insight capture across multi-day events. ZoomRx Ferma Congress is a leading offering in this category, and platforms with congress capabilities are particularly valuable during major events like ASCO, AHA, ASH, and ESMO.

Quick-Turn HCP Surveys

Modern HCP insights platforms support rapid-turn survey methodology with completion times measured in days, not weeks. Sermo RealTime reports 70% of surveys completed within 24-48 hours; ZoomRx Sagan delivers conversational HCP surveys with similar speed. Quick-turn studies typically focus on single-question or scoped multi-question surveys against verified HCP segments — useful for message testing, sentiment checks, and rapid response measurement following competitive events.

Standard Quantitative HCP Studies

Standard quantitative HCP studies — full-scale ATU studies, brand tracking waves, message testing batteries — typically run 4-8 weeks from kickoff to deliverable, depending on sample size, specialty mix, and depth of analysis required. Most pharma teams plan for 6 weeks as a working assumption when scoping standard quant HCP work, with longer timelines for global studies spanning multiple regions.

Qualitative HCP Research

Qualitative HCP research — IDIs, focus groups, advisory boards — typically runs 6-12 weeks depending on participant recruitment complexity, therapeutic area specificity, and number of sessions. Asynchronous advisory boards through platforms like Within3 can compress traditional advisory timelines significantly, with full advisory engagements running in 2-4 weeks compared to 8-12 weeks for traditional in-person advisory programs.

Synthetic and Decision Intelligence Modeling

Synthetic HCP modeling and decision intelligence platforms compress insights generation dramatically. Once calibrated against client research and category data, individual modeling cycles can run in 24-72 hours from question to deliverable. This is the operational advantage that defines the synthetic and decision intelligence category — making it possible to inform decisions inside campaign and launch windows that traditional HCP research cannot reach.

Launch Readiness and Pre-Launch HCP Programs

Comprehensive launch readiness programs combining multiple HCP insights methodologies typically run 6-12 months in the pre-launch window, with parallel workstreams covering message development, positioning testing, KOL engagement, advisory boards, and pre-launch awareness tracking. Pharma teams should plan launch-readiness HCP programs at least 12 months before anticipated launch to allow for full insights cycles.

Ongoing Brand Operations

Once a brand is launched, HCP insights operations typically settle into ongoing rhythms — quarterly ATU waves, monthly brand tracking, continuous social listening, ongoing advisory engagement, and ad hoc message testing as competitive disruptions emerge. The strongest pharma commercial operations integrate HCP insights as a continuous intelligence layer rather than discrete project-based engagements.

Panel Access and Per-Study Pricing

Traditional HCP panel platforms (Sermo, M3, Reckner) typically price per study or per survey, with costs driven by sample size, specialty mix, completion timeline, and depth of analysis. Standard quantitative HCP studies typically range from $25,000 for scoped quick-turn work to $150,000+ for comprehensive multi-specialty global studies. Hard-to-reach specialties (oncology subspecialties, rare disease) carry premium pricing due to recruitment difficulty.

Subscription and Platform Licensing

Platform-based offerings (Within3, ZoomRx, GlobalData, Acumen) typically operate on annual subscription models with tiered pricing based on user seats, feature access, and usage volume. Subscription pricing for enterprise HCP insights platforms typically runs $250,000 to $1.5M annually depending on platform, scope, and team size. Subscription models become more cost-effective as study volume increases — pharma teams running 10+ HCP studies annually typically save meaningfully versus per-study panel pricing.

Pilot and Conversion Pricing

Most platform-based offerings include pilot engagements ranging from $25,000 to $75,000 with conversion credit toward annual licensing. Acumen offers 90-day pilots with full conversion credit. ZoomRx and Within3 offer comparable pilot structures. Pilot pricing reflects calibration and integration effort rather than ongoing platform value, and most credible vendors price pilots to encourage serious evaluation rather than recover full cost.

Specialty Premium

Pricing for hard-to-reach specialties — pediatric oncology, rare disease, transplant medicine, specific orphan indications — typically runs 50-100% above baseline pricing due to panel recruitment costs and longer fielding timelines. Pharma teams operating in these specialties should budget accordingly and confirm specialty-specific recruitment capability during vendor evaluation.

Service-Led Engagements

Service-led HCP insights firms (Reckner, Evidera, custom Sermo concierge engagements) price per engagement with significant variation based on scope, methodology, and senior researcher involvement. These engagements typically run higher than self-serve platform pricing but include hands-on research design, custom recruitment, and bespoke analysis that platform-only offerings don't include.

Total Cost of Ownership

Beyond licensing and engagement fees, total cost of HCP insights operations includes internal team time for briefing, review, and synthesis, as well as integration with broader research workflows. Pharma teams typically underestimate the internal coordination cost of HCP insights operations — a factor that favors platforms with strong integration capabilities and managed service options.

Verified HCP Access at Scale

Access to verified, credentialed HCPs is the foundational asset of any credible HCP insights platform. Sermo's 1.5M+ triple-verified physician community, Within3's relationships with KOLs across all top 20 pharma companies, ZoomRx's proprietary 60,000+ HCP panel — these are assets that pharma teams cannot replicate internally and that take years to build. Platform partnerships provide immediate access to physician communities that would otherwise require dedicated panel infrastructure investment.

Specialty Depth Across Therapeutic Areas

Generic market research platforms struggle with the specialty-specific behavior patterns that pharma decisions require. HCP insights platforms with deep therapeutic area calibration — across oncology, immunology, cardiology, neurology, rare disease, and emerging specialties — produce materially better outputs than generalist tools adapted to pharma use cases. Specialty depth is a primary differentiator across the category.

Speed Without Sacrificing Methodology

Modern HCP insights platforms compress traditional research timelines dramatically while maintaining methodological rigor. Quick-turn survey capability, asynchronous advisory engagement, conversational AI methodology, and synthetic modeling all extend what's possible inside the time pressures of modern pharma commercial cycles. Speed is no longer a tradeoff against quality in this category — it's table stakes.

Regulatory and Compliance Infrastructure

Pharma HCP research operates within HIPAA, GDPR, sunshine act, and industry compliance frameworks that generic research tools often fail. Specialized HCP insights platforms have built-in compliance infrastructure for honoraria payment, FMV, transparency reporting, and adverse event handling that pharma procurement requires. Confirming compliance infrastructure during vendor evaluation is non-negotiable for enterprise pharma engagements.

Integration With Existing Pharma Research Stack

The strongest HCP insights platforms integrate cleanly with the broader pharma research ecosystem — IQVIA claims data, Kantar Health brand tracking, Veeva CRM, internal field intelligence, and proprietary research investments. Platforms that operate as additions to existing infrastructure rather than replacements convert more cleanly through enterprise pharma procurement and produce better outputs by leveraging existing data assets.

Multi-Stakeholder Modeling Capability

Modern HCP decisions don't happen in isolation — they're shaped by patient demand, payer coverage, MSL engagement, and institutional dynamics. The strongest HCP insights platforms increasingly model HCP behavior in context of these other stakeholders, producing integrated views of decision-making that single-stakeholder platforms cannot match. Decision intelligence platforms like Acumen extend this capability further by modeling HCPs alongside executives, regulators, and internal stakeholders for the cross-functional decisions that matter most.

Specialty and Therapeutic Area Coverage

Evaluate vendors specifically against the specialties and therapeutic areas your portfolio covers. A platform with strong oncology panel depth may have weaker coverage in cardiology or rare disease. Ask vendors specifically about panel composition, recruitment capability for hard-to-reach specialties, and historical engagement experience in your therapeutic areas. Specialty fit matters more than overall platform sophistication for most pharma evaluation criteria.

Panel Verification and Quality Standards

HCP panel quality varies meaningfully across the category. Triple-verified panels (Sermo standard) with active community engagement typically produce higher-quality outputs than panels relying on self-report verification or sparse engagement. Ask vendors about verification methodology, ongoing engagement metrics, response quality controls, and how they handle fraud and verification failures. Panel quality compounds — high-quality panels produce better insights study after study.

Methodology Mix and Innovation

Modern HCP insights platforms offer multiple methodologies — quantitative surveys, qualitative interviews, asynchronous advisory boards, conversational AI, synthetic modeling, and digital engagement signal. Evaluate which methodologies the platform supports natively versus through partnerships, and whether the methodology mix aligns with your team's research preferences. Vendors with broader methodology coverage typically support more pharma use cases without requiring multiple platform engagements.

AI and Synthetic Capability

The HCP insights category is rapidly incorporating AI augmentation and synthetic modeling. Evaluate where each vendor sits on this spectrum — pure traditional panel access, AI-augmented synthesis on top of panel data, or synthetic-native modeling grounded in research data. The strongest platforms combine multiple approaches and position AI as augmentation rather than replacement for verified HCP voice.

Compliance and Regulatory Infrastructure

Pharma HCP research compliance requirements are extensive — HIPAA, GDPR, sunshine act transparency, FMV honoraria, adverse event reporting, and pharmaceutical industry codes of conduct. Confirm in writing during evaluation whether the platform has SOC 2 Type II controls, signed BAAs and DPAs as standard practice, and explicit compliance infrastructure for pharmaceutical use cases. Generic AI vendors often lack this infrastructure; pharma-specialized vendors typically have it built in.

Integration With Existing Research Workflow

The platform should integrate cleanly with the research vendors and tools your team already uses. Ask vendors how they ingest data from existing partners, whether they connect to claims data, EHR-derived insights, and internal field intelligence, and how they handle vendor IP and contractual data-sharing requirements. Integration depth determines how much value a platform extracts from your existing research investments.

Pilot Discipline and Conversion Path

Most credible HCP insights vendors offer structured pilots with conversion credit toward annual subscriptions. Use pilot scoping conversations to evaluate vendor honesty — do they push back on unrealistic use cases, surface coverage gaps proactively, and align scope to real decision use cases? Vendors who say yes to everything are higher procurement risk than vendors who scope pilots carefully.